Is tesamorelin only for HIV patients?

FDA approval is specifically for HIV-infected patients with lipodystrophy. Off-label use for other populations (such as general aging or NAFLD) is not FDA-approved and should be discussed with a qualified clinician.

How does tesamorelin compare to sermorelin?

Both are GHRH analogs, but tesamorelin has a trans-3-hexenoic acid modification that increases receptor binding stability. Tesamorelin is FDA-approved for HIV lipodystrophy; sermorelin's approved brand (Geref) was discontinued, though sermorelin remains available through compounding.

What is the safest next step before starting tesamorelin?

Confirm the official indication fit, verify realistic cost and coverage friction, and then use a licensed provider route experienced in HIV metabolic care or hormone optimization.

Treatment hubFDA ApprovedDeep Dive

Tesamorelin Treatment Guide: Egrifta, HIV Lipodystrophy, and Provider Paths

In the United States, tesamorelin is approved as Egrifta for reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. It is also studied for liver fat reduction and cognitive preservation in aging.

Published: Apr 27, 2026Updated: Apr 27, 2026Medically reviewed: Apr 27, 2026Current

Medically Reviewed

This content was medically reviewed by James Patterson, MD, Board-Certified in Sports Medicine and Physical Medicine & Rehabilitation.

Last reviewed: April 27, 2026

Overview

Tesamorelin is a synthetic GHRH analog that stimulates the pituitary to release endogenous growth hormone. Unlike direct GH injections, tesamorelin preserves the natural pulsatile GH pattern and feedback axis. Its FDA-approved indication is HIV-associated lipodystrophy, but clinical interest extends to NAFLD and cognitive aging.

Approved Product Paths

Egrifta

Branded tesamorelin for HIV-associated lipodystrophy. Dosed at 2 mg SC once daily. Requires reconstitution before injection.

Egrifta SV

Same tesamorelin peptide as Egrifta in a different formulation. Used for the same indication with the same dosing schedule.

Benefits

•FDA-approved reduction of visceral adipose tissue in HIV-associated lipodystrophy
•Demonstrated reduction in liver fat fraction (NAFLD) in HIV-infected patients
•Preserves natural growth hormone pulsatility via pituitary stimulation
•Emerging evidence for cognitive function preservation in aging adults

Side Effects & Friction

•Injection site reactions including erythema, pruritus, and pain are common
•Fluid retention, peripheral edema, and arthralgia may occur
•Treatment should be discontinued if no reduction in visceral fat after 6 months
•Not indicated for general weight loss or cosmetic fat reduction outside approved populations

Administration Routes

Subcutaneous injection

Cost Reality

Tesamorelin costs vary by fulfillment channel and insurance. As a specialty medication for HIV lipodystrophy, it may be covered under some plans but often requires prior authorization and documentation of HIV status and lipodystrophy diagnosis.

Provider Path

The highest-value next step is finding a provider experienced in HIV metabolic care or hormone optimization who can evaluate whether tesamorelin fits the patient's clinical profile and insurance constraints.

How Tesamorelin Works

Tesamorelin is a synthetic 44-amino-acid peptide analog of growth hormone-releasing hormone (GHRH). It stimulates the pituitary to release endogenous growth hormone, which reduces visceral adipose tissue in HIV-associated lipodystrophy.

Tesamorelin binds to GHRH receptors on anterior pituitary somatotrophs, activating the Gs/cAMP/PKA pathway and triggering pulsatile GH secretion. The mechanism is identical to sermorelin but with higher potency and a modified structure that resists proteolytic degradation.

Unlike exogenous GH, tesamorelin preserves hypothalamic-pituitary negative feedback. Rising IGF-1 levels increase somatostatin tone, naturally limiting GH output. This makes supraphysiologic GH exposure and acromegaly risk extremely unlikely.

Growth hormone stimulates lipolysis in visceral adipocytes via hormone-sensitive lipase activation. Visceral fat is more responsive to GH-mediated lipolysis than subcutaneous fat, which explains the preferential reduction in trunk and abdominal fat seen in clinical trials.

GH also has anabolic effects on muscle, improves lipid profiles by reducing triglycerides, and may improve insulin sensitivity in the long term despite transient glucose elevations.

Tesamorelin is administered as a daily 2 mg subcutaneous injection, typically into the abdomen. The half-life is short, requiring daily dosing to maintain effect.

The drug was specifically developed and FDA-approved for HIV-associated lipodystrophy, a condition characterized by central fat accumulation and peripheral fat wasting in patients on antiretroviral therapy.

GHRH receptorAnterior pituitary somatotrophsGH receptor on visceral adipocytesHepatocytes

Clinical Trial Evidence

Phase 3 RCT (two identical trials)

PMID: 19846544

Population: HIV-infected adults with lipodystrophy and excess abdominal fat

N= 816

Duration: 26 weeks

Endpoint: Percent change in visceral adipose tissue (VAT) by CT

18% reduction in VAT vs 3% with placebo (p<0.001)
No significant change in subcutaneous adipose tissue
Triglycerides reduced by 50 mg/dL vs placebo
No significant change in glucose or insulin resistance over 26 weeks

Long-term extension study

PMID: 20539097

Population: Patients completing initial 26-week trials

N= 295

Duration: 52 weeks total

Endpoint: Sustained VAT reduction and safety

VAT reduction sustained at 52 weeks in continued treatment group
Rebound of VAT observed within 12 weeks after discontinuation
IGF-1 remained in normal range throughout
No new safety signals emerged with extended therapy

Dosing & Administration

HIV-associated lipodystrophy (Egrifta)Subcutaneous · Once daily

Starting: 2 mg once daily

Titration: No titration required; fixed dose

Maintenance: 2 mg once daily

Maximum: 2 mg once daily

•Reconstitute with 2 mL sterile water for injection
•Inject subcutaneously into abdomen; rotate sites
•Take at same time each day
•Do not inject into scar, bruised, or irritated tissue
•Use within 30 days of reconstitution; store in refrigerator

Side Effect Profile

Injection site

Erythemamild8%

Common; rotate sites

Pruritusmild5%

Usually transient

Painmild4%

Proper technique reduces incidence

Fluid retention

Peripheral edemamild4%

Usually mild and transient

Musculoskeletal

Arthralgiamild6%

Joint pain, usually mild

Myalgiamild3%

Muscle aches

Metabolic

Hyperglycemiamoderate5%

GH has anti-insulin effects; monitor glucose

IGF-1 elevationmildExpected

Usually stays within normal range

Contraindications & Warnings

Do Not Use

Hypothalamic-pituitary axis disruption (surgery, radiation, tumor, head trauma)
Active malignancy
Pregnancy or breastfeeding
Known hypersensitivity to tesamorelin or mannitol
Non-HIV lipodystrophy (not FDA-approved, limited data)

Important Warnings

May elevate blood glucose; monitor in patients with diabetes or prediabetes
Fluid retention may worsen heart failure
GH/IGF-1 mitogenic properties raise theoretical cancer concern; avoid in active malignancy
Discontinuation leads to VAT rebound within 12 weeks
Does not treat peripheral lipoatrophy (face, limbs); may worsen perception of peripheral wasting if trunk fat decreases disproportionately

Drug Interactions

Drug	Interaction	Severity	Mechanism
Antiretroviral therapy	None significant	minor	No known pharmacokinetic interactions with NRTIs, NNRTIs, PIs, or INSTIs
Insulin/oral hypoglycemics	May reduce efficacy	moderate	GH counter-regulates insulin; may increase insulin requirements transiently
Corticosteroids	May blunt response	moderate	Glucocorticoids suppress GH axis

Monitoring Requirements

IGF-1 at baseline and periodically (target upper-normal, not supraphysiologic)
Fasting glucose and HbA1c every 3 months
Visceral adipose tissue by CT or waist circumference every 6 months
Triglyceride levels
Signs of fluid retention or edema

How Tesamorelin Compares

Visceral fat reductionExogenous hGH advantage

Tesamorelin: 18% VAT reduction

Exogenous hGH: Similar magnitude

Tesamorelin achieves similar VAT loss with better safety profile

SafetyTesamorelin advantage

Tesamorelin: Feedback preserved; no overdose risk

Exogenous hGH: Supraphysiologic dosing possible

Tesamorelin cannot cause acromegaly

FDA indicationTesamorelin advantage

Tesamorelin: FDA-approved for HIV lipodystrophy

Sermorelin: Pediatric GH deficiency only

Tesamorelin has specific FDA approval for adult indication

StructureTesamorelin advantage

Tesamorelin: 44 amino acids, protease-resistant

Sermorelin: 29 amino acids, GHRH 1-29

Tesamorelin has longer half-life and greater potency

EfficacyTesamorelin advantage

Tesamorelin: 18% VAT loss

Lifestyle intervention alone: Minimal VAT change

Diet and exercise alone rarely produce significant VAT reduction in this population

Evidence Quality Assessment

Overall Evidence Grade: B

A = Strong evidence from multiple large RCTs

Human RCTs: Moderate: Two phase 3 RCTs with 816 patients, well-controlled

Long-term data: Limited: 52-week extension data; no cardiovascular outcomes

Real-world evidence: Limited: Post-marketing data focused on HIV population

Regulatory status: FDA-approved for HIV-associated lipodystrophy (Egrifta); off-label use for body composition is common but not FDA-approved

Is Tesamorelin Right for You?

Ideal Candidates

HIV-positive adults with excess abdominal fat and preserved pituitary function
Patients on stable antiretroviral therapy
Those frustrated by central fat accumulation that does not respond to diet/exercise
Patients without active malignancy or significant pituitary disease

Avoid

Patients with disrupted hypothalamic-pituitary axis
Active malignancy
Uncontrolled diabetes
Pregnancy or breastfeeding
Patients seeking treatment for peripheral fat loss (tesamorelin does not help lipoatrophy)

Use With Caution

Diabetes or prediabetes
History of cancer
Heart failure or fluid retention
Patients expecting peripheral fat restoration

Cost & Insurance Deep Dive

List Price (Monthly)

~$4,000-$5,000/month (Egrifta)

Cash-Pay Range

$3,500-$5,000/month; some patients access through patient assistance

Insurance Coverage Rate

~60-70% for HIV lipodystrophy with proper documentation

Prior Auth Likelihood

Very high; requires HIV diagnosis, lipodystrophy documentation, and failure of conservative measures

Savings Programs

Egrifta Patient AssistanceFree or significantly reduced cost

Eligibility: Uninsured or underinsured, income ≤500% FPL

Annual reapplication required

Manufacturer copay cardMay reduce out-of-pocket to $0-$100/month

Eligibility: Commercially insured

Not for government insurance

Cost-Effectiveness Notes

•High list price limits access despite FDA approval
•Patient assistance programs are essential for most patients
•No generic available; exclusivity protects pricing
•Cost per unit of VAT reduction is high compared to lifestyle interventions

Ready to find a tesamorelin provider?

Use the provider matcher to compare treatment paths by state, coverage, budget, urgency, and intake mode before committing to a prescribing workflow.

Find a tesamorelin provider

Recovery Support Products

Tools and supplements commonly used alongside hormone optimization protocols.

Deep-Tissue Foam Roller

Self-myofascial release to complement healing peptide protocols for tendons and soft tissue.

$20–40View on Amazon

Reusable Gel Ice Pack Wrap

Cold therapy reduces local inflammation — commonly used alongside BPC-157 and TB-500 research.

$12–25View on Amazon

Magnesium Glycinate Capsules

Highly bioavailable magnesium supports muscle recovery, sleep quality, and reduces cramping.

$15–30View on Amazon

Collagen Peptides Powder

Type I & III hydrolyzed collagen to support tendon, ligament, and joint repair.

$25–45View on Amazon

Amazon affiliate links; we may earn a small commission at no extra cost to you. See our disclosure.

Progress Tracking Tools

Monitor body composition, sleep, and recovery metrics.

Smart WiFi Body Scale

Tracks BMI, body fat %, and muscle mass — essential for monitoring GLP-1 progress over time.

$30–60View on Amazon

Digital Kitchen Food Scale

Precise gram-level portion tracking helps maximize weight loss results on GLP-1 therapy.

$10–20View on Amazon

Protein Shaker Bottle Set

Leak-proof mixing bottles for protein shakes — supports consistent protein intake on a smaller appetite.